Peptide Knowledge Base · Metabolic

Cagrilintide: what it is, what the evidence says, and its real status

Rarely discussed alone, almost always as the partner that makes a GLP-1 work harder (CagriSema, and the experimental LEAN pairing).

Can you actually get it?

Plain-English verdict: Join waitlist.

Regulatory status: Investigational (Phase 3).

How does Cagrilintide work?

A long-acting analog of amylin, the satiety hormone co-secreted with insulin; it slows gastric emptying and extends fullness, complementing GLP-1 appetite signaling.

What it does — and what it does not do

What it does: Studied as a satiety amplifier that adds to GLP-1 weight effects when combined.

What it does not do: It is not typically used alone; combination figures are trial-stage, not promises.

How honest is the evidence?

Evidence grade B — Good human evidence.

Phase-3 combination data (REDEFINE), re-verify against primary sources

A grade measures how much human evidence exists, not whether a molecule is good, safe, or worth your interest. Read our grading methodology for what each grade means.

What we still don't know: Standalone efficacy and long-term safety are less characterized than the combination; the program is ongoing.

WADA status: Not prohibited.

How it is taken

What the literature reports: subcutaneous, weekly. Educational only, no dose figures.

Who should not take it

Investigational, safety not fully characterized; clinician-gated. Class GI tolerability applies in combination.

Sources

REDEFINE / CagriSema Phase-3 program (ongoing, re-verify against primary sources)

Compounded medications are not FDA-approved. We keep two signals separate and never collapse them: whether you can get something, and what the rule currently says. See the live FDA Peptide Tracker for status.

Join the founding list →

Embed this card on your site · free, CC BY 4.0, no key.

Last reviewed Jun 18, 2026 · Peptós.LIFE · Not medical advice.